<DOC>
	<DOCNO>NCT00028600</DOCNO>
	<brief_summary>RATIONALE : Peripheral blood stem cell transplant use stem cell patient donor may able replace immune cell destroy chemotherapy use kill tumor cell . The donated stem cell may also help destroy remain cancer cell ( graft-versus-tumor effect ) . PURPOSE : This phase II trial study well autologous peripheral stem cell transplant follow donor peripheral stem cell transplant work treat patient multiple myeloma .</brief_summary>
	<brief_title>Peripheral Stem Cell Transplant Treating Patients With Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : - Determine whether autologous peripheral blood stem cell transplantation ( PBSCT ) follow non-myeloablative allogeneic PBSCT associate 20 % treatment-related mortality rate 6 month patient multiple myeloma . - Determine response rate patient treat regimen . - Determine percent donor chimerism patient treat regimen . - Determine rate graft-vs-host disease patient treat regimen . - Determine toxic effect regimen patient . - Determine disease-free overall survival patient treat regimen . - Determine whether abnormal cytogenetics presentation correlate poor response patient treat regimen . OUTLINE : This multicenter study . Patients receive cyclophosphamide IV 1-2 hour day 1 filgrastim ( G-CSF ) subcutaneously ( SC ) begin day 5 continue peripheral blood stem cell ( PBSC ) collection complete . Approximately 2-4 week PBSC collection , patient receive melphalan IV 15-30 minute day -2 . Patients undergo autologous PBSC transplantation ( PBSCT ) day 0 . Patients receive G-CSF SC begin day 5 continue blood count recover . Approximately 2-4 month autologous PBSCT , patient receive fludarabine IV 30 minute day -7 -3 cyclophosphamide IV 1 hour day -4 -3 . Patients undergo allogeneic PBSCT day 0 . Patients receive G-CSF SC begin day 7 continue blood count recover . Patients receive graft-vs-host disease ( GVHD ) prophylaxis comprise oral tacrolimus twice daily day -1 90 follow taper day 91-150 methotrexate IV day 1 , 3 , 6 . After day 120 , patient stable progressive disease evidence active GVHD may receive donor lymphocyte infusion ( DLI ) 2 hour . Patients may receive 3 DLIs every 8 week . Patients follow every 3 month 3 year , every 6 month 5 year , annually 15 year . PROJECTED ACCRUAL : A maximum 63 patient accrue study .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis active multiple myeloma require treatment DurieSalmon stage I , II , III No 1 progression initial therapy Must HLAidentical sibling donor ( 6/6 ) serologic typing ( A , B , DR ) No syngeneic donor Must also enrol protocol CLB8461 ( Cytogenetic Studies Acute Leukemia ) PATIENT CHARACTERISTICS : Age : Under 65 Performance status : NCI CTC 01 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count great 500/mm^3 Platelet count great 50,000/mm^3 Hepatic : Bilirubin le 2 mg/dL AST le 3 time upper limit normal ( ULN ) Alkaline phosphatase less 3 time ULN Renal : Creatinine le 2 mg/dL Creatinine clearance great 40 mL/min Cardiovascular : LVEF least 30 % MUGA scan Pulmonary : DLCO great 40 % predict No symptomatic pulmonary disease Other : HIV negative No uncontrolled diabetes mellitus No active serious infection Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 4 week since prior chemotherapy Prior alkylatingagent therapy allow 12 month duration Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy Surgery : At least 4 week since prior surgery Other : All prior therapy 18 month duration</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>